Note: This guideline has been updated. The National Guideline Clearinghouse (NGC) is working to update this summary.

Note: This guideline has been updated. The National Guideline Clearinghouse (NGC) is working to update this summary. The recommendations that follow are based on the previous version of the guideline.

Recommendations are followed by evidence grades (A-C) identifying the type of supporting evidence. Definitions of the evidence grades are presented at the end of the "Major Recommendations" field.

Consensus Statements for Antibiotic Prophylaxis during Gastrointestinal Endoscopic Procedures

Prophylaxis against Infective Endocarditis

1. For most endoscopic procedures, including upper endoscopy, sigmoidoscopy, and colonoscopy with or without mucosal biopsy, polypectomy, and/or nonvariceal hemostasis:
   1. Antibiotic prophylaxis is not recommended for patients with lesions at intermediate risk for the development of endocarditis, or those with lesions or conditions at no increased risk for endocarditis compared to the general population. For example patients with mitral valve prolapse, with or without regurgitation do not require prophylaxis for any of the above procedures.
   2. There are insufficient data to recommend routine prophylaxis for patients at "high risk" for infective endocarditis. The endoscopist may consider prophylaxis on a case-by-case basis.
2. For endoscopic procedures associated with increased rates of transient bacteremia, including dilation of an esophageal stricture, varix sclerotherapy, and retrograde cholangiography with known or suspected bile duct obstruction:
   1. Prophylaxis is recommended for patients at "high risk" for the development of endocarditis.
   2. No prophylaxis is recommended for patients with those cardiac lesions and conditions at no increased risk for infective endocarditis over the general population. However, it is recommended that all patients with suspected or known biliary obstruction should receive prophylactic antibiotics prior to endoscopic retrograde cholangiopancreatography (ERCP).
   3. There are insufficient data to recommend routine prophylaxis for patients with cardiac lesions or conditions at intermediate risk for the development of infective endocarditis. The endoscopist may consider prophylaxis on a case-by-case basis.
3. Regimens (Dajani et al, 1997):
   1. Standard general prophylaxis: amoxicillin 2.0 g orally (po) (adult) or 50 mg/kg po (child), 1 hour prior to the procedure. Alternative for those unable to take po is ampicillin 2.0 g intravenously or intramuscularly (IV/IM) (adult) or 50 mg/kg IV/IM (child), within 30 min before procedure.
   2. Penicillin-allergic patients: clindamycin 600 mg po (adult) or 20 mg/kg po (child), 1 hour prior to procedure. Alternatives: cephalexin or cefadroxil 2.0 g po (adult) or 50 mg/kg po (child), 1 hour prior to the procedure. Azithromycin or clarithromycin 500 mg po (adult) or 15 mg/kg po (child), 1 hour prior to procedure.
   3. Penicillin-allergic patients unable to take po: clindamycin 600 mg IV (adult) or 20 mg/kg IV (child), within 30 min before procedure. Alternative: cefazolin 1.0 gm IV/IM (adult) or 25 mg/kg IV/IM (child) within 30 min before the procedure. Vancomycin 1.0 gm IV (adult) or 10-20 mg/kg (child).

The Patient with a Synthetic Vascular Graft

For up to the first year after placement of a synthetic vascular graft, antibiotic prophylaxis is recommended for patients undergoing esophageal stricture dilation, varix sclerosis, or endoscopic retrograde cholangiography (ERCP) with known or suspected bile duct obstruction. For other endoscopic procedures, there are insufficient data to recommend routine prophylaxis. The endoscopist may consider prophylaxis on a case-by-case basis.

The Patient with a Prosthetic Joint or Orthopedic Prosthesis

There are insufficient data to recommend antibiotic prophylaxis for patients with prosthetic joints or orthopedic prostheses undergoing gastrointestinal endoscopic procedures.

The Patient with Biliary Obstruction, Pancreatic Pseudocyst, or Pancreatic Cystic Lesion Requiring Fine Needle Aspiration (FNA)

All patients undergoing ERCP for known or suspected biliary obstruction or known pancreatic pseudocyst should receive antibiotics along with adequate drainage of the biliary obstruction or cyst. Endoscopic transmural drainage of pancreatic pseudocysts similarly may result in the introduction of infection into the cystic cavity. Additionally, the endoscopic ultrasound (EUS) guided aspiration of pancreatic cystic lesions may also result in introduction of infection. Although not supported by randomized, controlled trials, the use of prophylactic antibiotics prior to attempted drainage of such pseudocysts and similar pancreatic lesions is recommended. Antibiotics which cover biliary flora such as enteric gram-negative organisms, enterococci, and possibly Pseudomonas sp. are recommended. Prophylactic antibiotics do not appear to be necessary prior to FNA of solid masses.

The Endoscopic Placement of a Percutaneous Feeding Tube

All patients undergoing percutaneous endoscopic placement of a feeding tube should receive prophylaxis to prevent soft tissue infection. Parenteral cefazolin (or an antibiotic with equivalent coverage) should be given 30 minutes prior to the procedure. If the patient is already on an equivalent antibiotic, prophylactic antibiotic administration remains unnecessary.

The Patient with Cirrhosis, Ascites, and the Immunocompromised Patient

Cirrhotic and otherwise immunocompromised patients are susceptible to infections from transient bacteremia, which occurs more often in high risk invasive procedures. The endoscopist should consider prophylaxis on a case-by-case basis in these high risk procedures such as esophageal sclerotherapy and stricture dilation. All cirrhotics presenting with gastrointestinal (GI) bleeding should receive prophylactic antibiotics.

For other endoscopic procedures including prophylactic endoscopic variceal ligation, routine antibiotic prophylaxis is not recommended. However, the decision to administer antibiotic prophylaxis should be made on a case-by-case basis. Cirrhotic patients with ascites appear to be at a potentially higher risk for infection. Additionally, transplant patients on high doses of steroids also appear to have increased susceptibility to infection. The choice of antibiotic should be tailored to the specific perceived risk.

Summary

• Antibiotic prophylaxis against infective endocarditis is recommended when a high risk patient is undergoing an endoscopic procedure associated with a high incidence for transient bacteremia (C).
• Patients undergoing high risk endoscopic procedures who have a synthetic vascular graft less than one year old should also receive antibiotic prophylaxis (C).
• There is no clear benefit or consensus in the use of prophylactic antibiotics in patients with a prosthetic joint or an orthopedic prosthesis undergoing any endoscopic procedure (C).
• All patients undergoing ERCP for known or suspected biliary obstruction or known pancreatic pseudocyst should receive antibiotics with adequate drainage of the biliary obstruction (A) or cyst (C).
• Prophylactic antibiotics are recommended for endoscopic ultrasound guided aspiration of pancreatic cystic lesions but not prior to FNA of solid masses (C).
• All patients undergoing endoscopic placement of a percutaneous feeding tube should receive prophylactic antibiotics to limit the risk of soft tissue infection (A).
• All patients with cirrhosis who present with GI bleeding should receive prophylactic antibiotics to decrease infectious complications and mortality (A).

Refer to Table 1 below where antibiotic prophylaxis for endoscopic procedures is summarized. There are insufficient data to provide definitive recommendations in certain circumstances. Other factors, including preferences of patients and referring physicians, must also be considered. It is strongly recommended that each endoscopy unit or center develop a policy appropriate for its specific practice. These recommendations may serve as a template for this process.

Definitions:

1. Prospective controlled trials
2. Observational studies
3. Expert opinion

None provided

The type of supporting evidence is identified and classifed for the recommendations using the following scheme:

1. Randomized controlled trials
2. Non-randomized studies
3. Expert opinion

Not applicable: The guideline was not adapted from another source.

2003 Oct

American Society for Gastrointestinal Endoscopy - Medical Specialty Society

American Society for Gastrointestinal Endoscopy

Standards of Practice Committee

Committee Members: Douglas O. Faigel, MD (Chair); William K. Hirota, MD; Kathryn Petersen, MD; Todd H. Baron, MD; Jay L. Goldstein, MD; Brian C. Jacobson, MD; Jonathan A, Leighton, MD; J. Shawn Mallery, MD; J. Patrick Waring, MD; Robert D. Fanelli (SAGES Representative); Jo Wheeler-Harbough, RN (SGNA Representative)

Not stated

Note: This guideline has been updated. The National Guideline Clearinghouse (NGC) is working to update this summary.

None available

None available

This NGC summary was completed by ECRI on April 16, 2004. The information was verified by the guideline developer on May 12, 2004.

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.